School of Medicine Publications
Document Type
Article
Publication Date
5-5-2025
Abstract
The availability of monoclonal antibodies directed against amyloid beta, for use as disease-modifying therapies for Alzheimer’s disease (AD), represented a major shift in the field of AD research and treatment. U.S. Food and Drug Administration approvals for the monoclonal antibody–based medications lecanemab and, more recently, donanemab provide clinicians with two antiamyloid therapy (AAT) options for targeting early symptomatic AD. The emergence of AAT has made careful biomarker-informed diagnosis of AD paramount, which was once reserved for highly specialized centers and research settings. Patient selection is complex, and although appropriate-use recommendations have been published, clinicians caring for patients with AD across the United States face uncertainty when trying to align clinical trial criteria, appropriate-use recommendations, and real-world patients in the clinic. Practical issues in patient selection as well as health care and systemic challenges in the implementation of AAT are considered in part 1 and part 2, respectively, of this two-part Treatment in Behavioral Neurology & Neuropsychiatry commentary on these therapies from the American Neuropsychiatric Association Dementia Special Interest Group.
Recommended Citation
Bateman, J. R., Carlisle, T. C., Yang, Y., Lachner, C., Stockbridge, M. D., Flashman, L. A., Chemali, Z., Alzbeidi, N., Pressman, P. S., Osibajo, A. M., Bobrin, B. D., Martinez-Menendez, C. J., Teixeira, A. L., Daffner, K. R., & American Neuropsychiatric Association Dementia Special Interest Group (2025). Antiamyloid Monoclonal Antibodies in Alzheimer's Disease, Part 1: Patient Selection. The Journal of neuropsychiatry and clinical neurosciences, 37(4), 371–377. https://doi.org/10.1176/appi.neuropsych.20240191
Publication Title
The Journal of neuropsychiatry and clinical neurosciences
DOI
10.1176/appi.neuropsych.20240191
Academic Level
faculty
Mentor/PI Department
Neurology
Comments
Published version will be freely available on May 5, 2026 via publisher site.